Brought to you by 
Murex and Digene expand DNA probe agreement
Jun 1994
Executive Summary
International Murex Technologies (infectious disease diagnostics) and Digene Diagnostics (DNA probe diagnostics) have expanded upon their collaborative agreement from last year, and Murex has made a $3 million equity investment in Digene.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Includes Equity
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Murex and Digene expand DNA probe agreement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice